The Role of DNA Methylation in Ganglion Cell Death
Principal Investigator
Shannath Merbs, MD, PhD
Johns Hopkins University School of Medicine
Baltimore, MD, USA
About the Research Project
Program
Award Type
Standard
Award Amount
$100,000
Active Dates
July 01, 2012 - June 30, 2014
Grant ID
G2012033
Co-Principal Investigator(s)
Raymond A. Enke, PhD, Johns Hopkins University
Goals
Although glaucoma is a common disease, little has been found in the way of a genetic contribution, suggesting that many genes and environmental factors may act together to cause the disease. In this study, Drs. Merbs, Enke, and colleagues are looking for “epigenetic” changes (modifications to the DNA that can be caused, in part, by the environment) in an animal model of glaucoma. They will also test whether manipulation of DNA methylation (a type of epigenetic change) improves retinal ganglion cell survival.
Summary
The goal of this study is to begin to define the contribution of non-genetic or “epigenetic” mechanisms causing retinal ganglion cell death in animal models of glaucoma. Drs. Merbs, Enke, and colleagues are comparing epigenetic differences in DNA methylation of the entire genome between healthy ganglion cells and ganglion cells from an animal engineered to have glaucoma. Identified differences will give clues as to what epigenetic changes contribute to the cell death seen in glaucoma. These researchers will then manipulate the DNA methylation in ganglion cells in culture and live animals to see the effects on ganglion cell survival.
While it is known that epigenetic mechanisms contribute to other common diseases such as cancer, very little is known about their contribution to the development and progression of glaucoma. Epigenetic mechanisms are particularly exciting because they represent a way that the environment can interact with one’s genes to cause susceptibility to the development of a disease. A better understanding of the contribution of epigenetic mechanisms to glaucoma could lead to totally new treatment strategies.
Related Grants
National Glaucoma Research
Understanding Optic Nerve Head Astrocyte Contributions to Glaucoma
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Evan Cameron, PhD
Current Organization
Cleveland Clinic - Lerner Research Institute
Understanding Optic Nerve Head Astrocyte Contributions to Glaucoma
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Evan Cameron, PhD
Current Organization
Cleveland Clinic - Lerner Research Institute
National Glaucoma Research
Exploring Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Glaucoma
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Qi Cui, MD, PhD
Current Organization
University of Pennsylvania, Perelman School of Medicine
Exploring Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Glaucoma
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Qi Cui, MD, PhD
Current Organization
University of Pennsylvania, Perelman School of Medicine
National Glaucoma Research
Reducing Inflammation to Protect Vision in Glaucoma
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Cátia Gomes, PhD
Current Organization
Indiana University School of Medicine
Reducing Inflammation to Protect Vision in Glaucoma
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Cátia Gomes, PhD
Current Organization
Indiana University School of Medicine